Data as of Jul 25
| -2.86 / -3.80%|
The 9 analysts offering 12-month price forecasts for Synageva BioPharma Corp have a median target of 115.00, with a high estimate of 140.00 and a low estimate of 89.00. The median estimate represents a +58.88% increase from the last price of 72.38.
The current consensus among 10 polled investment analysts is to Buy stock in Synageva BioPharma Corp. This rating has held steady since July, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.